Objective-Abdominal aortic aneurysm (AAA) is an increasingly prevalent and ultimately fatal disease with no effective pharmacological treatment. Because matrix degradation induced by vascular inflammation is the major pathophysiology of AAA, attenuation of this inflammation may improve its outcome. Previous studies suggested that miR-33 (microRNA-33) inhibition and genetic ablation of miR-33 increased serum high-density lipoprotein cholesterol and attenuated atherosclerosis. Approach and Results-MiR-33a-5p expression in central zone of human AAA was higher than marginal zone. MiR-33 deletion attenuated AAA formation in both mouse models of angiotensin II-and calcium chloride-induced AAA.
T he prevalence of abdominal aortic aneurysm (AAA) is increasing because of greater longevity and lifestyle changes. It is the third most common cause of cardiovascular death, accounting for 1% to 3% of all deaths in the male population >65 years old. 1 Early diagnosis by computed tomography scanning can be achieved in clinics, but drugs to prevent AAA growth are not available thus far. Because AAA progresses asymptomatically and can result in fatal rupture, 2 developing drug therapy to prevent AAA expansion is an urgent and unmet need. The lack of effective pharmacotherapy for AAA progression is partially because of poor understanding of the mechanisms of AAA occurrence, expansion, and rupture. Epidemiological and pathological studies have provided several clues to the pathophysiology of AAA. Current evidence suggests that inflammation of the aortic wall is a key step in vascular smooth muscle cell (VSMC) apoptosis, endothelial dysfunction, and proteinase activation, which together lead to destruction of the elastic media and fragility of the aortic wall. matrix metalloproteinase [MMP] , which is one of the major groups of proteinases in AAA pathogenesis) failed to show clear clinical effectiveness against AAA growth, 4 most likely because a wide variety of proteinases are involved in the pathogenesis of AAA. 5 Thus, inhibition of aneurysmal wall inflammation, a process that is upstream of proteinase activation, may be a novel therapeutic target. Several cohort studies and their meta-analyses showed that statins are the most reliable agents among currently available therapeutic options for the prevention of AAA progression and rupture although there are currently no large randomized control trials in progress. 6 Statins are thought to improve AAA prognosis through anti-inflammatory effects resulting from improved cholesterol metabolism and through pleiotropic effects, such as attenuation of protein prenylation.
Recent reports, including ours, have indicated that miR-33 (microRNA-33) regulates cholesterol metabolism by targeting ATP-binding cassette transporter A1 (ABCA1), thus reducing high-density lipoprotein cholesterol (HDL-C) levels, and miR-33 deficiency ameliorates atherosclerosis in mice. [7] [8] [9] [10] [11] MiRs are a well-defined species of noncoding RNAs, and evidence is accumulating that this class of genes plays crucial roles in many physiological and pathological processes. Indeed, several miRs affecting AAA have been reported; their targets include proteinases, extracellular matrix production, vascular cell homeostasis, and inflammation. 12 However, although clinical evidence also suggests that serum cholesterol level, 13 cholesterol efflux, 14 and ABCA1 polymorphism 15 are associated with AAA prevalence, there are no reports of miRs associated with cholesterol homeostasis and AAA. Here, we speculated that loss of miR-33 may exert a beneficial role on AAA formation in addition to having atheroprotective effects because anti-miR-33 treatments have anti-inflammatory properties 10 that are also observed in statin treatment. Indeed, circulating miR-33a-5p is reported to be elevated in patients with AAA compared with healthy controls. 16 In the present study, we found elevated miR-33 expression in central zones compared with in marginal zones in human AAA. As an interventional study, we investigated the effect of miR-33 deficiency in a mouse model of angiotensin II (AngII)-induced AAA, and then confirmed the effect of this deficiency on inflammation in a calcium chloride (CaCl 2 )-induced AAA model. In vitro experiments revealed that miR-33 deficiency reduced MMP9 expression levels in macrophages and MCP-1 (monocyte chemotactic protein-1) levels in VSMCs and augmented the anti-inflammatory effects of HDL-C. Finally, we performed bone marrow (BM) transplantation experiments using miR-33-deficient mice and showed that miR-33 deficiency in BM cells and other recipient cells had a distinct beneficial effect on AAA formation. These data strongly suggest that inhibition of miR-33 is a promising strategy for treating AAA.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MiR-33 Deletion Attenuates AAA Both in AngII and CaCl 2 Models
We compared the expression levels of miR-33 between the central and marginal zones of human AAA. Although miR33b-5p expression levels were not different, miR-33a-5p levels were elevated in the central zone compared with in the marginal zone in all samples analyzed ( Figure I in the onlineonly Data Supplement).
As interventional analyses, we conducted in vivo experiments using previously generated C57BL/6 background miR-33 −/− mice. 9 While humans have 2 homologues of miR-33 (a and b), rodents have only 1 miR-33 locus, which is equivalent to miR-33a. We developed a mouse model of AAA by continuous subcutaneous infusion of AngII for 4 weeks to Westerntype diet-fed C57BL/6 background Apoe Figure 1A and 1B). AAA was successfully induced, dissecting media, and generating pseudolumen, as reported previously 18 ( Figure  IIE in the online-only Data Supplement). The expression of miR-33 was elevated in AngII-treated suprarenal abdominal aortas ( Figure IIF in the online-only Data Supplement). The AAA diameter in DKO mice was significantly smaller than in single knockout mice ( Figure 1A-1C) , and AAA in DKO mice was less severe ( Figure 1D ), as determined using a previously reported severity scale for AAA 19 (briefly detailed in the Materials and Methods in the online-only Data Supplement). Moreover, whereas 40% of single knockout mice died from aortic dissection and rupture within 1 week after the initiation of continuous infusion of AngII, as reported previously, 20 significantly fewer (30.77%) DKO mice died within this period ( Figure 1E ). Next, we used another model in which AAA was induced by infrarenal periaortic application of CaCl 2 . 21 AAA was successfully induced compared with sham-operated mice (Figure 2A To determine the mechanisms underlying the attenuation of AAA in miR-33 −/− mice, we analyzed AAA walls at 7 days after the application of CaCl 2 . In this and subsequent experiments, we used the CaCl 2 model, in which AAA is induced purely by vascular inflammation rather than plaque formation, although the CaCl 2 -induced AAA model does not induce rupture or death. 22 Accumulation of CD68 + macrophages in AAA walls was assessed as a marker of inflammation in the AAA wall. Macrophage infiltration was reduced in miR-33 Moreover, the MMP9-positive area in the CD68-positive area was significantly reduced in miR-33 −/− mice compared with miR-33 +/+ mice ( Figure 2D ). It is known that monocytes originating from BM extravasate into vessel walls by chemoattractant-receptor interaction and subsequently differentiate into macrophages. Therefore, given that MCP-1 is a major chemoattractant of monocytes/ macrophages, we measured its expression level in the AAA wall. MCP-1 expression was significantly reduced in miR-33 Figure 3A) . In particular, Mmp9, which is a M1 marker, was significantly decreased in these cells. MMP9 activity in the conditioned medium of miR-33 −/− macrophages, as assessed by gelatin zymography, was also significantly reduced ( Figure 3B ). Finally, MMP9 expression was reduced in miR-33 knocked-down THP-1 macrophages ( Figure VIA in the onlineonly Data Supplement).
Tumor necrosis factor α (TNFα) is thought to be one of the central cytokines in AAA progression, and it acts by inducing the release of proteases that degrade the extracellular matrix. 24 Thus, we analyzed Mmp9 expression in macrophages stimulated by TNFα and found attenuated Mmp9 expression in miR-33 −/− macrophages ( Figure 3C ). MiR-33 was reported to increase the M1/M2 marker ratio in macrophages directly targeting AMP-activated protein kinase α1 (AMPKα1). Figure 3E ). Although ABCA1, which is one of the well-known miR-33 targets, was indeed elevated in miR-33 −/− macrophages ( Figure VIC in the onlineonly Data Supplement) as reported previously. 9 To investigate whether ABCA1 is involved in the Mmp9 expression in macrophages, we performed siRNA-mediated knockdown of ABCA1. Both miR-33 +/+ and miR-33 −/− macrophages showed similar levels in Mmp9 in the condition of siRNA-mediated knockdown of ABCA1 ( Figure 3F ).
However, it was reported that c-Jun N-terminal kinase (JNK), one of inflammatory mitogen-activated protein kinase (MAPK), upregulated MMP9, and JNK inhibition caused the regression of AAA formation. 24 Therefore, we analyzed JNK activity in macrophages with or without TNFα stimulation. Western blotting analysis of macrophages revealed significantly reduced JNK activity in miR-33 −/− macrophages after TNFα stimulation ( Figure 3G ). In contrast, p38 MAPK, the other inflammatory MAPK, was unchanged between the groups ( Figure VID in the online-only Data Supplement). Moreover, JNK inhibition by SP600125 canceled the effect of miR-33 deletion on Mmp9 expression in peritoneal macrophages ( Figure 3H ). It is known that ABCA1 knockout activate JNK pathway. 25 Thus, MMP9 downregulation in miR-33 −/− macrophages was suspected to be mediated by reduced JNK activity through the increase of ABCA1 levels. Although macrophages are thought to be another source of MCP-1, there was no difference in the concentration of MCP-1 in macrophage-conditioned medium between the 2 groups ( Figure VIE in the online-only Data Supplement).
Deletion of MiR-33 Attenuates MCP-1 Expression in VSMCs
In immunohistochemical analysis in mouse aortas, MCP-1 was colocalized with α smooth muscle actin ( Figure IVA It is known that p38 MAPK is crucial for the regulation of MCP-1.
26,27 Thus, we examined p38 MAPK activity in miR-33 −/− VSMCs after TNFα stimulation and found that its activity was significantly lower than that in miR-33 
HDL-C in MiR-33 −/− Mice Has Augmented Anti-Inflammatory Properties in Macrophages and VSMCs
Whereas HDL-C levels were reported to increase with miR-33 inhibition 7,11 and miR-33 deficiency, 9 the antiinflammatory effects of HDL-C, 28 such as MMP9 reduction in macrophages 29 and MCP-1 reduction in VSMCs, 30 are well-known. Therefore, we examined the effect of HDL-C on TNFα-induced MMP9 expression in macrophages. Compared with controls, human-derived HDL-C at 0.1 or 0.5 mg/mL reduced Mmp9 expression in peritoneal macrophages in a dose-dependent manner ( Figure 5A ). Next, we compared the effect of HDL-C against Mmp9 expression in macrophages using HDL-C derived from miR-33 +/+ (wild-type HDL) and miR-33 −/− (knockout HDL) mice. Knockout HDL mice showed more beneficial effects against TNFα-induced Mmp9 expression in macrophages than wild-type HDL ( Figure 5B ). Moreover, HDL-C reduced MCP-1 expression in rat VSMCs in a dose-dependent manner ( Figure 5C ), and this effect was much more prominent in knockout HDL compared with wild-type HDL mice ( Figure 5D ). Taken together, these results indicated that wild-type HDL exhibited more potent anti-inflammatory effects than knockout HDL. Figure 6D) . Thus, the difference in HDL-C levels was thought to be a recipient effect of AAA attenuation in miR-33 −/− mice. These results suggested that both recipient effects (HDL-C and VSMCs) and donor effect (macrophages) contributed considerably to the reduction of AAA formation in miR-33 −/− mice.
Discussion
We used 2 distinct mouse AAA models and in vitro experiments to demonstrate that genetic deletion of miR-33 suppressed AAA formation by several different mechanisms: serum HDL-C elevation, as well as MMP9 reduction in macrophages and MCP-1 reduction in VSMCs, through suppression of JNK and p38 MAPK activity, respectively. We also analyzed the contribution of previously known miR-33 target genes. AMPKα1 was shown to be upregulated by the inhibition of miR-33 and suppress the inflammatory phenotypes in macrophages. 13 However, there was no effect of AMPKα1 knockdown on the difference in Mmp9 expression between miR-33 +/+ and miR-33 −/− macrophages. However, ABCA1 knockdown abolished the difference in Mmp9 expression between these macrophages. Moreover, knockdown of ABCA1 in primary mouse VSMCs eliminated the difference in MCP-1 expression levels between wild-type and miR-33 −/− mice (Graphical Abstract).
In both models, miR-33 deletion attenuated AAA formation. Macrophage infiltration and MMP9 expression in macrophages were attenuated in miR-33 −/− AAA walls. MCP-1, the major chemoattractant of monocytes/macrophages, was also decreased in miR-33 −/− mice. These results were consistent with previous study that reported miR-33-mediated M1/M2 marker elevation and reduction of serum MCP-1 levels in antimiR-33-treated mice. 10 Serum HDL-C levels in BM-transplanted miR-33 −/− mice revealed that the main contributor of serum HDL-C elevation in miR-33 −/− mice was not deletion of miR-33 in BM cells. This result was consistent with a previous report in Abca1 −/− mice, 31 which revealed that reduced serum HDL-C levels in Abca1 −/− mice were because of a lack of ABCA1 in the liver and not to BM cells. These results suggested that serum HDL-C elevation in miR-33 −/− mice was caused mainly by hepatic ABCA1 elevation. In relation to AAA, serum HDL-C or apolipoprotein A1 levels were reported to negatively correlate with AAA prevalence and progression, and the effect of HDL-C on AAA was thought to be much stronger than its effect on preventing plaque formation because inflammatory mechanisms are more important for AAA. Furthermore, the ABCA1/HDL interaction itself is thought to have distinct antiinflammatory effects. 32 As mentioned in the first paragraph, statins were reported to be the most reliable agents for preventing AAA progression and rupture, 6 and several supportive basic research studies indicated that the mechanisms underlying this effect were anti-inflammation resulting from improved cholesterol metabolism and distinct pleiotropic effects, such as attenuation of protein isoprenylation. 33, 34 Taken together with speculation on the anti-AAA effects of statins, AAA may be effectively prevented by anti-inflammation and improved cholesterol metabolism, the latter because of either statins or anti-miR-33. MiRs can be suppressed by antisense oligonucleotides, some of which, including anti-miR-33, are currently being investigated in clinical or preclinical trials. 35, 36 In contrast, statins are also known to increase miR-33 and decrease ABCA1 expression. 37 Thus, miR-33 inhibition by an antisense oligonucleotide in combination with statins may enhance the anti-AAA effect of statins. At the same time, these results suggested that the combination of improving cholesterol metabolism and achieving distinct antiinflammation should be targeted for developing more effective strategies to improve AAA prognosis, whereas many pathways are said to affect AAA.
In summary, miR-33 deletion ameliorated AAA formation in CaCl 2 -and AngII-induced AAA models, and an in vitro study and BM transplantation experiments showed that attenuated expression of MMP9 in macrophages as a donor effect and elevated HDL-C levels and reduced MCP-1 expression in VSMCs as recipient effects are all thought to contribute to the reduction of AAA in miR-33 −/− mice. A novel miR-33/cholesterol axis in AAA pathogenesis was uncovered in this study, and these results strongly suggest that inhibition of miR-33 may be a novel therapeutic strategy for AAA. 
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